Understanding existing antipsychotics and newer drug targets in schizophrenia

A. Avinash, Sushil Kiran Kunder, Anurag Pathak, Navin Patil, Veena Nayak

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Schizophrenia is a chronic, debilitating, prototypic psychotic disorder, which has antipsychotics as the mainstay of treatment. Antipsychotics are broadly divided into two: Typical and atypical. While typical drugs were popular in clinical practice until a few years ago, there are slowly being replaced by the atypical drugs, mainly because of improved efficacy and lesser incidence of extra-pyramidal symptoms. However, the newer drugs have their own demerits, in the form of other adverse effects, like metabolic syndrome, QT prolongation and sudden death. Several newer targets have been identified in the field, which might help in bringing about drugs with improved efficacy and safety parameters.

Original languageEnglish
Pages (from-to)1507-1520
Number of pages14
JournalResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Issue number1
Publication statusPublished - 01-01-2016

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Understanding existing antipsychotics and newer drug targets in schizophrenia'. Together they form a unique fingerprint.

Cite this